ecrin-mdr-crcClinical2016IPD Sharing (as of September 2020): NoC18-9Metastatic Colorectal CancerColorectal NeoplasmsMalignant neoplasm of colonC18-9Metastatic Colorectal CancerColorectal NeoplasmsMalignant Neoplasm Of ColonInterventionalhttps://newmdr.ecrin.org/Study/2254808IranAland Islands10IrinotecanLeucovorinFluorouracilBevacizumabECRIN MDRCompletedfalseComparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal CancerThis is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation. This trial was conducted to evaluate the efficacy and safety of bevacizumab (produced by AryoGen Pharmed) plus FOLFIRI-3 compared with bevacizumab (Avastin) plus FOLFIRI-3 in patients with metastatic colorectal cancer (mCRC). Patients who met the following criteria could be recruited to receive the mentioned intervention randomly. Inclusion criteria: male or female aged 18-75 years, mCRC verified histologically, Having one or more bi-dimensionally measurable lesions as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, Was not felt to be amenable to curative resection, With an (ECOG) performance status of ≤ 1, Life expectancy of longer than 3 months, Adequate organ and marrow function, May have received adjuvant therapy for primary colorectal cancer provided that at least 6 months have elapsed from the time the adjuvant therapy was concluded and recurrent disease was documented, Patients with history of hypertension must be well-controlled (blood pressure less than/equal to 150/100), on a stable regimen of anti-hypertensive therapy.2016-10-152254808NCT03288987IRCT2015072517994N2